The White House announced new agreements with nine pharmaceutical companies to lower prescription drug prices Friday.

Bank of America reaffirmed its Buy rating for Eli Lilly, setting a price target of $1,268. Analyst Jason Gerberry noted that the trial data strengthens the company's competitive stance against rival ...

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

Novo Nordisk A/S (NYSE:NVO) is one of the Best Non-US Stocks to Buy According to Hedge Funds. On December 12, Novo Nordisk ...

Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi have agreed to drug pricing deals.

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...

In his latest effort to lower drug costs, President Donald Trump unveiled Friday “Most Favored Nation” pricing deals with nine more pharmaceutical companies.

Makers of Ozempic and other weight loss drugs are facing lawsuits that allege the drugs cause blindness in some patients.

A handful of drugmakers have already disclosed pricing deals with the Trump administration and plan to sell certain drugs at a discount on TrumpRx, the White House's new direct-to-consumer website ...

GLP-1s improved outcomes in patients with heart failure with preserved ejection fraction, with or without obesity, but those ...

The pharmaceutical sector's most intense rivalry is escalating. Eli Lilly has unveiled pivotal Phase 3 trial results for its ...